Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] surged by $0.07 during the normal trading session on while it closed the day at $0.67.
Adaptimmune Therapeutics Plc ADR stock has also loss -14.98% of its value over the past 7 days. However, ADAP stock has declined by -43.29% in the 3 months of the year. Over the past six months meanwhile, it has lost -37.52% and lost -14.91% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for ADAP stock reached $172.55 million, with 227.17 million shares outstanding and 226.31 million shares in the current float. Compared to the average trading volume of 1.40M shares, ADAP reached a trading volume of 5439825 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Adaptimmune Therapeutics Plc ADR [ADAP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADAP shares is $2.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADAP stock is a recommendation set at 1.89. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Adaptimmune Therapeutics Plc ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 30, 2024. While these analysts kept the previous recommendation, Scotiabank raised their target price to Sector Outperform. The new note on the price target was released on May 30, 2024, representing the official price target for Adaptimmune Therapeutics Plc ADR stock. Previously, the target price had yet another raise to $3.60, while Bryan Garnier analysts kept a Buy rating on ADAP stock.
The Average True Range (ATR) for Adaptimmune Therapeutics Plc ADR is set at 0.07, with the Price to Sales ratio for ADAP stock in the period of the last 12 months amounting to 0.98. The Price to Book ratio for the last quarter was 2.16, with the Price to Cash per share for the same quarter was set at 0.73.
ADAP stock trade performance evaluation
Adaptimmune Therapeutics Plc ADR [ADAP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -14.98. With this latest performance, ADAP shares dropped by -18.09% in over the last four-week period, additionally sinking by -37.52% over the last 6 months – not to mention a rise of 40.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADAP stock in for the last two-week period is set at 39.45, with the RSI for the last a single of trading hit 41.10, and the three-weeks RSI is set at 39.02 for Adaptimmune Therapeutics Plc ADR [ADAP]. The present Moving Average for the last 50 days of trading for this stock 0.8602, while it was recorded at 0.6436 for the last single week of trading, and 1.1214 for the last 200 days.
Adaptimmune Therapeutics Plc ADR [ADAP]: An insightful look at the core fundamentals
Adaptimmune Therapeutics Plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.82 and a Current Ratio set at 3.85.
Earnings per share (EPS) analysis for Adaptimmune Therapeutics Plc ADR [ADAP] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADAP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adaptimmune Therapeutics Plc ADR go to 1.00%.
Adaptimmune Therapeutics Plc ADR [ADAP]: Institutional Ownership
There are presently around $60.27%, or 60.49%% of ADAP stock, in the hands of institutional investors. The top three institutional holders of ADAP stocks are: MATRIX CAPITAL MANAGEMENT COMPANY, LP with ownership of 38.97 million shares, which is approximately 16.1135%. ECOR1 CAPITAL, LLC, holding 27.4 million shares of the stock with an approximate value of $$26.72 million in ADAP stocks shares; and ECOR1 CAPITAL, LLC, currently with $$16.65 million in ADAP stock with ownership which is approximately 7.0614%.
